Palvella Therapeutics (PVLA) Property, Plant & Equipment (Net) Growth (3y) (2016 - 2023)
Powered by 
Analysis
Palvella Therapeutics (PVLA) Property, Plant & Equipment (Net) Growth (3y) (2016 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 14.05% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.65% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 411.50% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -3.34% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 16.78% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.66% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 19.96% |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -7.63% |
| Mar 31, 2023 | -6.36% |
| Dec 31, 2022 | -4.49% |
| Sep 30, 2022 | 13.03% |
| Jun 30, 2022 | 30.25% |
| Mar 31, 2022 | 56.76% |
| Dec 31, 2021 | 55.87% |
| Sep 30, 2021 | 61.14% |
| Jun 30, 2021 | 64.26% |
| Mar 31, 2021 | 66.49% |
| Dec 31, 2020 | 76.14% |
| Sep 30, 2020 | 83.63% |
| Jun 30, 2020 | 88.02% |
| Mar 31, 2020 | 89.43% |
| Dec 31, 2019 | 104.99% |
| Sep 30, 2019 | 65.06% |
| Jun 30, 2019 | 47.72% |
| Mar 31, 2019 | 30.33% |
| Dec 31, 2018 | 32.66% |
| Sep 30, 2018 | 34.46% |